These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 20857891

  • 1. The relative safety of pooled whole-blood-derived platelets prepared by the buffy-coat method versus single-donor (apheresis) platelets.
    Vamvakas EC.
    Clin Lab; 2010; 56(7-8):263-79. PubMed ID: 20857891
    [Abstract] [Full Text] [Related]

  • 2. Pooled platelet concentrates: an alternative to single donor apheresis platelets?
    Pietersz RN.
    Transfus Apher Sci; 2009 Oct; 41(2):115-9. PubMed ID: 19716340
    [Abstract] [Full Text] [Related]

  • 3. [Single-donor (apheresis) platelets and pooled whole-blood-derived platelets--significance and assessment of both blood products].
    Hitzler WE.
    Clin Lab; 2014 Oct; 60(4):S1-39. PubMed ID: 24779310
    [Abstract] [Full Text] [Related]

  • 4. A critical comparison of platelet preparation methods.
    Vassallo RR, Murphy S.
    Curr Opin Hematol; 2006 Sep; 13(5):323-30. PubMed ID: 16888436
    [Abstract] [Full Text] [Related]

  • 5. Relative risk of reducing the lifetime blood donation deferral for men who have had sex with men versus currently tolerated transfusion risks.
    Vamvakas EC.
    Transfus Med Rev; 2011 Jan; 25(1):47-60. PubMed ID: 21134626
    [Abstract] [Full Text] [Related]

  • 6. Consistency and proportionality in policy decision-making in blood safety: the case for an all-apheresis platelet supply in Germany.
    Vamvakas EC, Hitzler WE.
    Clin Lab; 2013 Jan; 59(1-2):1-22. PubMed ID: 23505902
    [Abstract] [Full Text] [Related]

  • 7. Pathogen reduction of blood components.
    Solheim BG.
    Transfus Apher Sci; 2008 Aug; 39(1):75-82. PubMed ID: 18602343
    [Abstract] [Full Text] [Related]

  • 8. Quality of platelet concentrates derived by platelet rich plasma, buffy coat and Apheresis.
    Vasconcelos E, Figueiredo AC, Seghatchian J.
    Transfus Apher Sci; 2003 Aug; 29(1):13-6. PubMed ID: 12877887
    [Abstract] [Full Text] [Related]

  • 9. Donor selection criteria to maximize double platelet products (DPP) by platelet apheresis.
    Wollersheim J, Dautzenberg M, van de Griendt A, Sybesma B.
    Transfus Apher Sci; 2006 Apr; 34(2):179-86. PubMed ID: 16574489
    [Abstract] [Full Text] [Related]

  • 10. A national survey of transfusion-related acute lung injury risk reduction policies for platelets and plasma in the United States.
    Kleinman S, Grossman B, Kopko P.
    Transfusion; 2010 Jun; 50(6):1312-21. PubMed ID: 20456690
    [Abstract] [Full Text] [Related]

  • 11. Platelet concentrates, from whole blood or collected by apheresis?
    van der Meer PF.
    Transfus Apher Sci; 2013 Apr; 48(2):129-31. PubMed ID: 23535511
    [Abstract] [Full Text] [Related]

  • 12. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred?
    Schrezenmeier H, Seifried E.
    Vox Sang; 2010 Jul 01; 99(1):1-15. PubMed ID: 20059760
    [Abstract] [Full Text] [Related]

  • 13. Donor exposures in recipients of pooled platelet concentrates: a case-study in arithmetic, logic, "expert opinion", and the "peer review" process.
    Vamvakas EC, Hitzler WE.
    Clin Lab; 2013 Jul 01; 59(3-4):415-20. PubMed ID: 23724633
    [Abstract] [Full Text] [Related]

  • 14. Implementation of a strategy to prevent TRALI in a regional blood centre.
    Insunza A, Romon I, Gonzalez-Ponte ML, Hoyos A, Pastor JM, Iriondo A, Hermosa V.
    Transfus Med; 2004 Apr 01; 14(2):157-64. PubMed ID: 15113380
    [Abstract] [Full Text] [Related]

  • 15. Automated platelet collection using the latest apheresis devices in an Indian setting.
    Agarwal P, Verma A.
    Transfus Apher Sci; 2009 Oct 01; 41(2):135-8. PubMed ID: 19709930
    [Abstract] [Full Text] [Related]

  • 16. Use of random versus apheresis platelet concentrates.
    Andreu G, Vasse J, Sandid I, Tardivel R, Semana G.
    Transfus Clin Biol; 2007 Dec 01; 14(6):514-21. PubMed ID: 18417401
    [Abstract] [Full Text] [Related]

  • 17. [Platelet concentrates from whole-blood donations (buffy-coat) or apheresis: which one to use?].
    Lozano ML, Rivera J, Vicente V.
    Med Clin (Barc); 2012 May 05; 138(12):528-33. PubMed ID: 21807386
    [Abstract] [Full Text] [Related]

  • 18. Relative safety of pooled whole blood-derived versus single-donor (apheresis) platelets in the United States: a systematic review of disparate risks.
    Vamvakas EC.
    Transfusion; 2009 Dec 05; 49(12):2743-58. PubMed ID: 19682339
    [Abstract] [Full Text] [Related]

  • 19. Update on pathogen reduction technology for therapeutic plasma: an overview.
    Solheim BG, Seghatchian J.
    Transfus Apher Sci; 2006 Aug 05; 35(1):83-90. PubMed ID: 16934528
    [Abstract] [Full Text] [Related]

  • 20. [Quality of thrombocyte preparations from buffy coat or platelet-rich plasma].
    Bux J, Müller K, Misterek J, Mueller-Eckhardt C.
    Beitr Infusionsther; 1990 Aug 05; 26():99-102. PubMed ID: 1703912
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.